Laboratory Influenza Response

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

1 Isolation and Quarantine Protocol Public Health Seattle and King County 2004.
Alabama Primary Health Care Association
Surveillance in a Pandemic: Situational Awareness
Use of Tracers as a Leadership Tool
Chapter 1 The Study of Body Function Image PowerPoint
Copyright © 2011, Elsevier Inc. All rights reserved. Chapter 6 Author: Julia Richards and R. Scott Hawley.
Author: Julia Richards and R. Scott Hawley
1 Copyright © 2013 Elsevier Inc. All rights reserved. Appendix 01.
Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.
UNITED NATIONS Shipment Details Report – January 2006.
RXQ Customer Enrollment Using a Registration Agent (RA) Process Flow Diagram (Move-In) Customer Supplier Customer authorizes Enrollment ( )
Document #07-2I RXQ Customer Enrollment Using a Registration Agent (RA) Process Flow Diagram (Move-In) (mod 7/25 & clean-up 8/20) Customer Supplier.
1 Assessing Health Needs Gilbert Burnham, MD, PhD Johns Hopkins University.
1 HIV Drug Resistance Training Module 7: HIV Genotyping Assay Validation.
HIV Drug Resistance Training
1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.
State of New Jersey Department of Health and Senior Services Patient Safety Reporting System Module 2 – New Event Entry.
Properties of Real Numbers CommutativeAssociativeDistributive Identity + × Inverse + ×
Exit a Customer Chapter 8. Exit a Customer 8-2 Objectives Perform exit summary process consisting of the following steps: Review service records Close.
DCLS Influenza Laboratory Testing Denise M. Toney, Ph.D. Commonwealth of Virginia Division of Consolidated Laboratory Services H & M Panel – May 2009.
FACTORING ax2 + bx + c Think “unfoil” Work down, Show all steps.
Year 6 mental test 10 second questions
Real Time under an IDE – CDCs PCR and ELISA Investigational Protocols.
Site Safety Plans PFN ME 35B.
REVIEW: Arthropod ID. 1. Name the subphylum. 2. Name the subphylum. 3. Name the order.
1 How to Enter Time. 2 Select: Log In Once logged in, Select: Employees.
EMS Checklist (ISO model)
Effectively applying ISO9001:2000 clauses 6 and 7.
Unit 5: Choosing an HIV Test
1. 1.To gain a basic understanding of the Support Services Pathway. 2.To discover career options available within the Support Services Pathway. 3.To explore.
Replacement Reagent Policy Update
1 Preparing for Smallpox: Post-event Smallpox Response.
1 CIFTclinic 1.1 Software for Clinics. 2 CIFTclinic Software for Medical Clinics, which addresses the requirements of practicing doctors to automate Medical.
2 |SharePoint Saturday New York City
VOORBLAD.
2014 National Patient Safety Goals
Module 14: Blood Collection and Handling Dried Blood Spot
Factor P 16 8(8-5ab) 4(d² + 4) 3rs(2r – s) 15cd(1 + 2cd) 8(4a² + 3b²)
Basel-ICU-Journal Challenge18/20/ Basel-ICU-Journal Challenge8/20/2014.
1..
CONTROL VISION Set-up. Step 1 Step 2 Step 3 Step 5 Step 4.
© 2012 National Heart Foundation of Australia. Slide 2.
Understanding Generalist Practice, 5e, Kirst-Ashman/Hull
Introduction to Pandemic Influenza
Functional Areas & Positions
Model and Relationships 6 M 1 M M M M M M M M M M M M M M M M
25 seconds left…...
Analyzing Genes and Genomes
Unit 4: Specimen and Data Collection # Warm Up Questions: Instructions  Take five minutes now to try the Unit 4 warm up questions in your manual.
We will resume in: 25 Minutes.
©Brooks/Cole, 2001 Chapter 12 Derived Types-- Enumerated, Structure and Union.
Essential Cell Biology
Intracellular Compartments and Transport
PSSA Preparation.
Essential Cell Biology
1 Chapter 13 Nuclear Magnetic Resonance Spectroscopy.

Avian Influenza: Laboratory Issues Jill Taylor, Ph.D. Director, Clinical Virology Program Wadsworth Center.
SPECIMEN HANDLING: from patient bedside to the laboratories (clinical, commercial and public health) Patricia A. Somsel, Dr.P.H. Michigan Department of.
Laboratory Diagnostics and Specimen Collection. Learning Objectives Know the basic components of specimen collection kits for use with suspect avian influenza.
Information Exchange for Detection and Monitoring: Clinical Care to Health Departments Janet J Hamilton, MPH Florida Department of Health.
INFLUENZA SURVEILLANCE Julie L Freshwater, MPH PhD Influenza Surveillance Coordinator.
Laboratory Results and Operations in WHO Phase 6 Dr. Attaporn Taweetungtragoon CYBELES Phnom Penh, Cambodia October 12-15, 2009.
Laboratory Response to the 2009 H1N1 Event Texas Department of State Health Services Laboratory Services Section Grace Kubin, Ph.D. Vanessa Telles, MPH.
Ebola preparedness and Response in Lao PDR. Outline Objective The preparedness contingency plan Phase 1: Preparedness Phase 2: Contingency for response.
Patricia A. Somsel, Dr.P.H. Michigan Department of Community Health
Presentation transcript:

Laboratory Influenza Response Kerri Gerage Laboratory Emergency Response Coordinator Louisiana Office of Public Health Laboratory

Disclosure I have no financial interests or other relationship with manufacturers of commercial products, suppliers of commercial services, or commercial supporters. My presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.

Objectives Describe the Office of Public Health Laboratory’s mission for Influenza Testing Recognize the OPH Lab capabilities and capacity Discuss acceptable sample types and proper shipping methods

Public Health Mission Pandemic Influenza Testing NOT Diagnostic Testing Determine when and where influenza viruses are circulating Determine how much influenza activity is occurring Identify types and strains of circulating influenza viruses in addition to the pandemic strain Monitor for mutations in the influenza virus strains Detect unusual events: Infection by unusual viruses Unusual syndromes caused by influenza viruses Unusual large/severe outbreaks of influenza Increased mortality

Challenges NOT encountered THIS TIME Limitations or absence of lab reagents, supplies, PPE, etc Worker absenteeism (ie. personal illness, family issues, quarantine) Disruptions of medical and community services Need to suspend other critical lab services

Current Role in Influenza Testing Tests human specimens for influenza virus year-round according to OPH guidelines: Seasonal influenza surveillance (Sentinel providers) Investigation of respiratory illness outbreaks (ID Epi) Surveillance for novel influenza virus in humans If case meets OPH and CDC clinical and epidemiologic criteria for possible novel influenza infection

OPH Laboratory Capabilities Infrastructure available from ongoing preparedness efforts and planning Dedicated molecular laboratories Multiple real time PCR instruments and platforms Experienced molecular and virology staff 24 hours a day, 7 days a week emergency response capability Influenza collection kits on hand

Overview of OPH Laboratory Testing FDA cleared – Emergency Use Authorization, CDC developed test for Influenza A, B, and for sub-typing H1, swH1, H3 (and if needed H5) All tests will be performed by real-time rt-PCR First five confirmed positive Influenza A swH1 specimens are referred to CDC for drug resistance testing each week

What has OPH Done to be Ready for Future Influenza Pandemics? We have cross-trained additional staff Added some additional equipment Will have additional clerical staff trained for data entry Rearranged the Laboratory to allow for more efficient work-flow

Additional Biological Safety Cabinets for Specimen Processing

Additional Automated Nucleic Acid Extraction Equipment

Additional Real Time PCR Equipment

How Was Testing Handled Differently in the OPH Laboratory in the Spring ‘09 and now? In the Spring - wide spread testing to characterize a new virus and its spread A large number of isolates were tested A large number of isolates were sent to CDC Currently - limited targeted testing as needed Representative isolates will be sent to CDC

How is Testing be Handled Differently in Clinical Laboratories FDA (Emergency Use Authorization) has cleared the first commercially available Influenza A swH1 assay for clinical use; others will follow Some Commercial Laboratories currently have non-FDA approved, CLIA compliant Influenza A swH1 kits Diagnostic test manufacturers are ramping up production of rapid test kits

Specimen Submissions Specimens will only be accepted from: Influenza Sentinel Submitters selected by the Infectious Diseases Epidemiology Program From hospitalized patients that meet the criteria set by ID Epidemiology No general population or clinical testing

Current Acceptable sample types Nasopharyngeal swab: Tip of a polyester or Dacron swab placed in a transport vial containing 2.0ml of viral transport medium Throat washing: 3-5 ml of sterile PBS gargled and placed in a transport vial containing 2.0 ml of viral transport medium Throat swab: Tip of a polyester or Dacron swab placed in a transport vial containing 2.0 ml of viral transport medium Nasal washing: 3-7 ml of sterile PBS used to wash the patient’s nasal passage put into a sterile transport vial with viral transport medium Nasal swab: Tip of a polyester or Dacron swab placed in a vial containing 2.0 ml of viral transport medium

Sample Collection Samples must be collected using a Dacron, polyester, or rayon swab with a plastic or aluminum shaft Specimens must arrive in sealable bag placed inside of an insulated cooler Patient sample collection swabs must be placed in collection tubes with Viral Transport Media. Transport media must be specifically for viral transport. Media used to transport specimens for bacterial, fungal or parasite examinations are not acceptable When collecting samples from a patient suspected of having H1N1, a new swab should be collected to send to the OPH Lab. Do not send the same swab that was used for the Rapid Test

How to submit a Specimen Place the swab in Viral Transport Media Make sure Viral Transport Media Has Not Expired Put the date and time of collection on the tube along with the patient’s name

Fill out the Submission Form Completely Incomplete forms delay testing Common Errors No Fax Number No time or date of collection Illegible

Packaging Flu Samples Obtain a Category B mailer Place frozen ice packs on the bottom of the Styrofoam ice chest Place wet ice in a sealable bag on top of the froze ice packs Place the sample in viral transport media in another sealable bag with absorbent material on top of the wet ice Fill another sealable bag with wet ice to put on top of the samples Place 2 more frozen ice packs on top of the wet ice

Ship to the OPH Laboratory Overnight in a Category B Mailer

Why all these details? Proper specimen collection, packaging and shipping ensure a quality specimen is analyzed Federal Regulators require that these procedures be followed. Non-compliance can result in fines and closure of the laboratories responsible

Who will get the Laboratory Results The following people all get the patient test results at the same time-as soon as they are verified Infectious Disease Epidemiology Person or Agency that Submitted the Specimen by Fax if the number is provided by mail if fax number is not provided

What Restrictions are there on Releasing Laboratory Results? HIPPA regulations require that patients health data be protected from disclosure Patients have to authorize the release of their lab results to third parties The OPH Laboratory will only release lab results to the submitter of record on the submission form without the patients permission The only exception is for public health use

Upcoming Changes to Influenza Testing FDA Emergency Use Authorization will expire soon Acceptable sample sources for testing may change Temperature requirements will expand from 2- 4° C to 2- 8° C The acceptable time frame for getting refrigerated samples to the lab will decrease from 96 hrs to 72 hrs

Upcoming Changes to Influenza Testing Letter will be faxed to all submitters explaining the changes Report terminology may change slightly

Additional Lab Space Installed a Modular BSL 3 Adds additional lab space Adds additional testing capablilities

Modular BSL 3

Modular BSL 3

Modular BSL 3

Modular BSL 3

Modular BSL 3

Modular BSL 3

Modular BSL 3